Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

OUP Management Co., LLC 13F Holdings -- Portfolio & Top Positions (2023-09-30)

OUP Management Co., LLC (CIK 1880124) reported $44.5M across 12 reported positions in its SEC 13F filing for 2023-09-30. Largest positions: CNTA ($19.0M, 42.74%), JBIO ($8.2M, 18.43%), CYT ($7.0M, 15.71%), PMVP ($6.1M, 13.66%), LENZ ($1.0M, 2.27%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1CNTACentessa Pharmaceuticals plc$19.0M42.74%2.9MHold
2JBIOAerovate Therapeutics Inc.$8.2M18.43%603,762Hold
3CYTCyteir Therapeutics, Inc.$7.0M15.71%2.5MHold
4PMVPPMV Pharmaceuticals, Inc.$6.1M13.66%989,232Hold
5LENZGraphite Bio$1.0M2.27%406,308Hold
6SELBSelecta Biosciences, Inc.$914,2962.06%862,543Hold
7VORVor Biopharma Inc.$794,3941.79%374,714Hold
8EFTReFFECTOR Therapeutics, Inc.$615,3161.38%1.0MHold
9DTILPrecision BioSciences, Inc.$383,5920.86%1.1MHold
10SPROSpero Therapeutics, Inc. $301,3750.68%249,070Hold
11IKNAIkena Oncology, Inc.$116,1870.26%26,833New
12QTTBHomology Medicines, Inc.$74,8800.17%64,000Hold
13DICEDICE Therapeutics Inc.$00.00%0Exited

Source: SEC Form 13F filings · as of 2023-09-30